An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 24, 2004

Primary Completion Date

December 6, 2013

Study Completion Date

December 6, 2013

Conditions
Acromegaly
Interventions
DRUG

Pasireotide

Trial Locations (10)

1011

Novartis Investigative Site, Lausanne

2650

Novartis Investigative Site, Edegem

4102

Novartis Investigative Site, Woolloongabba

10010

NYU / VA Medical Center, New York

31043

Novartis Investigative Site, Toulouse Cédex 4

45122

Novartis Investigative Site, Essen

48109

University of Michigan Health System StudyCoordinatorCSOM230B2201E1, Ann Arbor

80131

Novartis Investigative Site, Napoli

80336

Novartis Investigative Site, München

90048

Cedars Sinai Medical Center Dept. of Pituitary Ctr., Los Angeles

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY